Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

RECOVERY (plasma), 2021
 
NCT04381936
RCTconvalescent plasma treatmentcontrolCOVID 19 hospitalizedsome concern
5795/5763 inconclusive 0% -1%
Balcells, 2020
 
NCT04375098
RCTconvalescent plasma treatmentconvalescent plasma treatmentCOVID 19 hospitalizedlow
28/30 inconclusive 290% -30%
ConCOVID (Gharbharan et al.), 2020
 
NCT04342182
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
43/43 inconclusive -5%
ConPlas-19, 2020
 
NCT04345523
RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
38/43 inconclusive -78% -5%
Abolghasemi, 2020
 
IRCT20200325046860N1
OBSconvalescent plasma treatmentcontrolCOVID 19 hospitalizedcritical
115/74 inconclusive -41%

COVID-19 mild to moderate meta-analysis

Libster, 2020
 
NCT04479163
RCTconvalescent plasma treatmentplaceboCOVID-19 mild to moderatelow
80/80 conclusif -45%
PLACID, 2020
 
CTRI/2020/04/024775
RCTconvalescent plasma treatmentstandard of careCOVID-19 mild to moderatehigh
235/229 suggested 4%

COVID-19 severe or critically meta-analysis

O’Donnell, 2021
 
NCT04359810
RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
150/73 inconclusive -48% 34%
AlQahtani, 2020
 
NCT04356534
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive
ILBS-COVID-02 (Bajpai M), 2020
 
NCT04346446
RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallyhigh
14/15 inconclusive 254%
Li, 2020
 
ChiCTR2000029757
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
52/51 inconclusive -37% 36%
PICP19 (Ray), 2020
 
CTRI/2020/05/025209
RCTconvalescent plasma treatmentcontrolCOVID-19 severe or critically
bias due to deviations from intended interventions some concern
bias due to missing outcome data low
bias in measurement of the primary outcome low
bias in selection of the reported result high
" >high
40/40 inconclusive -29% PlasmAr, 2020
 
NCT04344535 RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallylow
228/105 inconclusive -6% -17% PlasmAr, 2020
 
NCT04344535 RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
228/105 inconclusive -6% -17% Rasheed, 2020 RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallyNA
21/28 inconclusive -79% Duan, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
10/10 inconclusive -79% Hegerova, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
20/20 inconclusive -67% Sean, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
39/156 inconclusive -49% Joyner, 2020
 
NCT04338360 NRaconvalescent plasma treatmentconvalescent plasma treatmentCOVID-19 severe or criticallyserious
515/561 inconclusive 16%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).